Gilead's deal of a lifetime.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 19430443.
- Also identified by DOI 10.1038/nbt0509-423.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Gilead Sciences' ascent to the upper echelon of biotech centered around one very savvy acquisition that launched an HIV franchise.
Medical subject headings
- Anti-HIV Agents
- Drug Industry
- Drug Therapy, Combination